We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02581657
First Posted: October 21, 2015
Last Update Posted: March 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
PhaseBio Pharmaceuticals Inc.
  Purpose
This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with type 2 diabetes mellitus (T2DM) in up to four cohorts.

Condition Intervention Phase
Type 2 Diabetes Mellitus Drug: PE0139 Injection Drug: Placebo Injection Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by PhaseBio Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Safety and tolerability (as assessed by incidence and severity of adverse events (AEs), hypoglycemia and changes from baseline in vital signs, ECGs and safety laboratory parameters). [ Time Frame: AEs and hypoglycemia (Day -60 to 63), Vital signs (Days -60, -10, 0, 7, 14, 21, 28, 35, 42, 49 and 63), safety laboratory parameters (-60, -10, 14, 28, 42, 49 (as needed), and 63) ECGs (-60, -10, 14, 28, 42, 49 (as needed) and 63). ]
    To evaluate the safety and tolerability (as assessed by incidence and severity of AEs, hypoglycemia and changes from baseline in vital signs, ECGs and safety laboratory parameters) of multiple ascending doses of PE0139 administered as once weekly injection for 6 weeks in adults with T2DM.


Secondary Outcome Measures:
  • Pharmacokinetic (PK) profile - Area under the curve over the dosing interval (AUC (0-t)) [ Time Frame: PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose). ]
    Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.

  • Pharmacokinetic (PK) profile - Area under the curve concentration-time profile from 0 to Tmax [AUC (0-tmax)] and from Tmax to t [AUC(tmax-t] [ Time Frame: PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose). ]
    Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.

  • Pharmacokinetic (PK) profile - Maximum serum concentration (Cmax) [ Time Frame: PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose). ]
    Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.

  • Pharmacokinetic (PK) profile - Time to Cmax (Tmax) [ Time Frame: PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose). ]
    Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.

  • Pharmacokinetic (PK) profile - Elimination Rate Constant (Lamda z) [ Time Frame: PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose). ]
    Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.

  • Pharmacokinetic (PK) profile - Elimination half-life (t1/2) [ Time Frame: PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose). ]
    Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.

  • Pharmacokinetic (PK) profile - Clearance (CL/F), uncorrected for bioavailability [ Time Frame: PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose). ]
    Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.

  • Pharmacokinetic (PK) profile - Volume of Distribution (Vz/F), uncorrected for bioavailability [ Time Frame: PK measured for Dose 1 (pre-dose, 1, 3, 6 hours post-dose, daily for 6 days), Doses 2-5 given on days 7, 14, 21 and 28, respectively, (pre-dose) and Dose 6 (pre-dose, 1, 3 and 6 hours post dose, daily for 10 days and 14 days post-dose). ]
    Characterize the PK profile of PE0139 following 6 weeks repeat, once-weekly dosing to explore dose response relationship.

  • Pharmacodynamic (PD) Profile - Change from baseline in fasting plasma glucose [ Time Frame: PD response measured as fasting plasma glucose (FPG) (daily by subject up to day 21 and Days -60, between days -10 and -7, 0, 1-7, 14, 21, 28, 35, 36-49 and 63 at CRU) ]
    Characterize the PD response of various doses of PE0139 and glucose (as assessed by fasting and non-fasting plasma glucose)

  • Pharmacodynamic (PD) Profile - Change from baseline in average glucose by CGM [ Time Frame: PD response measured by continuous glucose monitoring (CGM) (baseline collected ≥7 days pre-dose daily after dose 3 for 4 weeks) ]
    Characterize the PD response of various doses of PE0139 and glucose (as assessed by CGM)

  • Fructosamine changes [ Time Frame: Measured at pre-dose and 7 days after last dose ]
    Assess the effect of various doses of PE0139 on change in fructosamine following 6 weeks of repeat, once-weekly dosing.

  • Required dose adjustment to background therapy [ Time Frame: All scheduled and unscheduled visits (Days -60 to 63) ]
    Assess the incidence for required dose adjustment to background therapy across various doses of PE0139 and compared to placebo.

  • Reported hypoglycemic events (% of subjects experiencing severe and non-severe hypoglycemic events) [ Time Frame: All scheduled and unscheduled visits (Days -60 to 63) ]
    Describe incidence, severity, and duration of reported hypoglycemic events across various doses of PE0139 and compared to placebo. Reported as % of subjects experiencing a hypoglycemic event (severe (requiring medical assistance or ≤36 mg/dL glucose) or non-severe (not requiring medical assistance and <70mg/dL glucose))

  • Binding anti-drug antibodies to PE0139 and insulin (as needed). If positive, neutralizing activity will also be assessed. [ Time Frame: Collected at Pre-dose, Days 7, 14, 21, 28, 35, 42, 49, 63 and 91. ]
    Characterize the immunogenicity profile (binding drug antibodies to PE0139 and insulin (as needed) and neutralizing antibodies if noted to be positive) following 6 weeks of repeat, once-weekly dosing.


Enrollment: 37
Study Start Date: October 2015
Study Completion Date: November 2016
Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PE0139 Injection
PE0139 Subcutaneous Injection - 6 weekly doses
Drug: PE0139 Injection
PE0139 Injection
Placebo Comparator: Placebo Injection
Placebo Subcutaneous Injection - 6 weekly doses
Drug: Placebo Injection
Placebo Injection

Detailed Description:

This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with T2DM in up to four cohorts; (6 active/2 placebo subjects in cohort 1, and up to 9 active/4 placebo in each subsequent cohort).

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic response of PE0139 in the presence of existing stable non-insulin antidiabetic background therapy. Subjects will return weekly for a total of 6 doses of study drug.

Study remains active, not recruiting as subjects who received active study drug will be followed for secondary outcome measures.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to sign a written informed consent and follow all study-related procedures;
  • Male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study drug;
  • Body mass index ≥ 18 kg/m2 and ≤ 45 kg/m2;
  • Diagnosed with T2DM with HbA1c of ≥ 7.5% and <11.0% and who is currently taking a non-insulin antidiabetic therapy at stable dose(s) for 3 months prior to screening;
  • Willing and able to comply with all study procedures including wearing a continuous glucose monitoring device and performance of frequent self-monitored blood glucose profiles according to the protocol;
  • Minimum 7-day average daily glucose of 154 mg/dL (based on CGM) at baseline evaluation;
  • Willing to refrain from taking acetaminophen (paracetamol) containing products (e.g., Tylenol®) 24 hours prior to the placement of the CGM device and throughout the time period when the CGM device is worn;
  • Live and work in an area with reliable Verizon cellular service for transmission of glucose data required for use of the Telcare Glucose Monitoring System.

Exclusion Criteria:

  • Clinical diagnosis of Type 1 diabetes;
  • Currently taking or have routinely taken, within 6 months prior to screening, a long or short-acting insulin;
  • Self-reported significant change in weight defined as either a loss or gain ≥ 10% during the three month period prior to screening or between screening and randomization;
  • Known allergy to, or serious adverse effect caused by an approved, or investigational insulin product or any of its components;
  • Currently taking any of the following medications: thiazide or furosemide diuretics, beta-blockers, estrogens or other hormonal replacement therapy, or other chronic medications with known adverse effects on glucose tolerance levels unless the subject has been on stable doses of such agents for at least 2 months prior to screening and have no planned changes in concomitant medication usage during the study period;
  • Self-reported history of severe hypoglycemia or hypoglycemic unawareness, as judged by the Investigator;
  • Self-reported history of acute complications secondary to diabetes within the last 6 months prior to screening or signs or symptoms of clinically significant diabetes related complications prior to screening;
  • Malignant disease defined as: Self-reported history of malignant melanoma or breast cancer; Self-reported history of other types of cancer (excludes basal/squamous cell carcinoma or cervical carcinoma if treated and condition not currently active) within the last 5 years prior to screening;
  • Unstable cardiovascular disease defined as one or more of the following: Self-reported history of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to screening; Self-reported history of or currently have NYHA Class III-IV heart failure prior to screening; Self-reported history of unstable angina within 3 months prior to screening; Uncontrolled/sustained hypertension; Self-reported history of clinically significant ECG abnormalities or evidence of clinically significant ECG abnormalities;
  • Clinically significant renal and/or hepatic dysfunction noted on safety labs;
  • Absolute requirement for corticosteroids or have routinely received systemic steroids within 12 months prior to randomization or use of inhaled corticosteroids within 1 month prior to randomization. A single short course treatment of systemic steroids to treat an acute infection will not exclude the subject if taken more than 3 months from screening;
  • Pregnant or lactating female subjects;
  • Known history of alcohol abuse or use of illicit drugs within 1 year prior to screening, and/or who test positive for alcohol and illicit drugs prior to randomization. Note: A subject will be considered in violation of the study if they test positive prior to any planned dosing and will be discontinued from the study;
  • Positive screening for human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies at screening;
  • Previously received PE0139;
  • Participating in any other study and have received any other investigational medication or device within 30 days prior to screening or are taking part in a non-medication study which, in the opinion of the Investigator, would interfere with the outcome of the study;
  • Other medical or psychiatric condition which, in the opinion of the Investigator, would place the subject at increased risk or would preclude obtaining voluntary consent or would confound the secondary objectives of the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02581657


Locations
United States, Alabama
Pinnacle Research Group, LLC
Anniston, Alabama, United States, 36207
United States, California
National Research Institute
Huntington Park, California, United States, 90255
United States, Florida
Meridien Research
Bradenton, Florida, United States, 34208
Indago Research and Health Center, Inc.
Hialeah, Florida, United States, 33012
United States, Louisiana
New Orleans Center for Clinical Research
New Orleans, Louisiana, United States, 70119
United States, Washington
Rainier Clinical Research
Renton, Washington, United States, 98057
Sponsors and Collaborators
PhaseBio Pharmaceuticals Inc.
  More Information

Responsible Party: PhaseBio Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT02581657     History of Changes
Other Study ID Numbers: PE0139-PT-CL-0002
First Submitted: October 9, 2015
First Posted: October 21, 2015
Last Update Posted: March 14, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases